4.6 Article

Cutting Edge: IL-2 Immune Complexes As a Therapy for Persistent Virus Infection

Journal

JOURNAL OF IMMUNOLOGY
Volume 182, Issue 8, Pages 4512-4515

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0804175

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R01 CA103642, R01 CA103642-05, CA103642, P30 CA023108, R01 CA103642-06A1] Funding Source: Medline
  2. NIAID NIH HHS [AI069943, R01 AI069943-02, T32AI07363, R56 AI069943, R01 AI069943, T32 AI007363] Funding Source: Medline

Ask authors/readers for more resources

There is an urgent need to develop novel therapies for controlling recurrent virus infections in immune suppressed patients. Disease associated with persistent, gamma-herpesvirus infection (EBV, HHV-8) is a significant problem in AIDS patients and transplant recipients, and clinical management of these conditions is difficult. Disease occurs because of a failure in immune surveillance to control the persistent infection, which arises in AIDS patients principally because of an erosion of the CD4(+) T cell compartment. Immune surveillance failure followed by gamma-herpesvirus recrudescence can be modeled using murine gamma-herpesvirus in CD4 T cell-depleted mice. We show that enhancement of IL-2 signaling using IL-2/anti-IL-2 immune complexes substantially improves immune surveillance in the context of suppressed immunity and enhances control of the infection. This effect was not due solely to increased numbers of virus-specific CD8 T cells but rather to enhanced cytotoxicity mediated by the perforin-granzyme pathway. The Journal of Immunology, 2009, 182: 4512-4515.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available